Short Versus Long Protocol for IVF and IVF+ICSI (KvL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00756028|
Recruitment Status : Completed
First Posted : September 19, 2008
Last Update Posted : January 13, 2016
Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to
- frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure)
- quality of life (2. outcome measure)
- live birth rate (2. outcome measure)
- gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol and vascular endothelial growth factor in follicular fluid(not only compared between GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS and patients becoming pregnant and not becoming pregnant (2. outcome measure), and
- number of oocytes removed per treatment, number of embryo transfers per treatment and number of spontaneous abortions per treatment (these three parameters are tertiary outcome measures).
In addition to the above mentioned efficacy outcome measures the safety outcome measure "frequency of known side-effects" will be compared between the two protocols.
|Condition or disease||Intervention/treatment||Phase|
|Infertility Ovarian Hyperstimulation Syndrome Quality of Life Live Birth||Drug: Patients receiving short protocol IVF/ICSI-treatment. Drug: Long protocol||Phase 4|
Patients: 1100 patients are randomized prospectively to either treatment. Stratification: =<36 y/>36 y, IVF/ICSI, and treatment centre.
Methods: OHSS is quantified by consecutive measurements of weight, abdominal diameter, ultrasound measurements of ascites and ovarian volume, paraclinical parameters, and by a systematic patient questionnaire. Furthermore it is registered if the patients have been hospitalized and/or have had ascites drainage performed due to OHSS. Data from the first 100 patients are used together with Golans OHSS-classification, to make a more precise definition of OHSS. This definition is applied prospectively on data from the remaining patients.
Quality of life is gauged by a questionnaire. Child birth rate is ascertained by a pregnancy response questionnaire and by obtaining data from the Danish National Birth Registry.
Statistics: The study is designed to be able to show a 50% reduction of OHSS comparing short to long protocol.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1099 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2015|
Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
Drug: Patients receiving short protocol IVF/ICSI-treatment.
Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
Active Comparator: 2
Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
Drug: Long protocol
Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
- Frequency of Ovarian Hyperstimulation Syndrome (OHSS) [ Time Frame: 3 years ]
- Quality of life during treatment [ Time Frame: 3 years ]
- Live births [ Time Frame: 3 years ]
- Gene expression profiles of granulosa and cumulus cells [ Time Frame: 3 years ]
- Estradiol and vascular endothelial growth factor concentrations in follicular fluid. [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00756028
|Dronninglund Fertility Clinic|
|Dronninglund, Denmark, 9330|
|Fertility Clinic, Hvidovre Hospital|
|Hvidovre, Denmark, 2650|
|Study Chair:||Thue Bryndorf||Hvidovre University Hospital|
|Study Chair:||Helle Meinertz||Hvidovre University Hospital|
|Principal Investigator:||Peter Hornnes||Hvidovre University Hospital|